News

Mission Therapeutics was established in 2011 to commercialize expert research into the ubiquitin pathway to treat cancers and other unmet medical needs. The company built a platform to

The FDA’s Fast Track program facilitates the development and review of drugs intended to treat serious conditions and address an unmet medical need. A drug development program with

The Company also reiterated its previous guidance that it expects to report data from the APOLLO study in 2017, and due to the competitiveness of this timing, it

Matinas BioPharma president and CEO Roelof Rongen said: "The encouraging preclinical data demonstrating MAT2501’s oral bioavailability and its targeted delivery of amikacin directly to the site of infection

Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, includingEliquis (apixaban). Bristol-Myers

The conjugate is subsequently labeled with indium-111 (111In) and other potential radioisotopes for in vivo diagnostic imaging and treatment of cancers. Panacea Pharmaceuticals COO Steven Fuller said: "Panacea

Truvada was approved by the EMA in 2005 in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults, and is currently the most prescribed

Kathy Niakan, a group leader at the Francis Crick Institute in London, will lead the research and use the CRISPR-Cas9 genome-editing technique in healthy human embryos. The researchers

The company’s vaccines division, Sanofi Pasteur, will use its expertise in developing vaccine for the virus. Sanofi Pasteur has developed vaccines against viruses in the same family as